Skip to main content
Log in

Moderate-Term Effect of Epoprostenol on Severe Portopulmonary Hypertension

  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

We examined the effect of continuous intravenous infusion of epoprostenol (35 ng/kg/min) on severe portopulmonary hypertension caused by biliary atresia. Pulmonary hemodynamics improved and brain natriuretic peptide and human atrial natriureic peptide decreased to normal values during epoprostenol therapy. However, the improvement in pulmonary hemodynamics was not sufficient to permit liver transplantation. Our patient was obliged to stop epoprostenol therapy because of financial problems and epoprostenol was tapered off safely over 6 weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kato, H., Katori, T., Nakamura, Y. et al. Moderate-Term Effect of Epoprostenol on Severe Portopulmonary Hypertension . Pediatr Cardiol 24, 50–53 (2003). https://doi.org/10.1007/s00246-002-0120-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-002-0120-9

Keywords

Navigation